Market Overview - The chemical pharmaceutical sector increased by 0.82% on the previous trading day, with Jinshi Yao leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Top Gainers in Chemical Pharmaceutical Sector - Jinshi Yao (300434) closed at 11.39, up 11.78% with a trading volume of 640,000 shares and a turnover of 714 million yuan [1] - Guangji Pharmaceutical (000952) closed at 7.06, up 9.97% with a trading volume of 215,600 shares and a turnover of 150 million yuan [1] - New Ganjing (920367) closed at 23.21, up 9.02% with a trading volume of less than 37,000 shares and a turnover of 85.7 million yuan [1] - Lingkang Pharmaceutical (603669) closed at 5.97, up 7.37% with a trading volume of 327,700 shares and a turnover of 192 million yuan [1] - Xiangdi Pharmaceutical (301211) closed at 13.12, up 6.84% with a trading volume of 190,800 shares and a turnover of 249 million yuan [1] Top Losers in Chemical Pharmaceutical Sector - Anglikang (002940) closed at 38.92, down 6.58% with a trading volume of 210,700 shares and a turnover of 829 million yuan [2] - Shutaishen (300204) closed at 36.99, down 5.57% with a trading volume of 394,900 shares and a turnover of 1467 million yuan [2] - Yatai Pharmaceutical (002370) closed at 7.00, down 4.76% with a trading volume of 1,532,900 shares and a turnover of 1061 million yuan [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 421 million yuan from institutional investors and 643 million yuan from speculative funds, while retail investors saw a net inflow of 1.063 billion yuan [2][3] - Jinshi Yao (300434) had a net inflow of 98.99 million yuan from institutional investors, while retail investors had a net outflow of 71.82 million yuan [3] - Guangji Pharmaceutical (000952) saw a net inflow of 39.50 million yuan from institutional investors, but a net outflow of 23.01 million yuan from retail investors [3]

Core Viewpoint - The A-share market is experiencing a surge in flu-related stocks, driven by rising flu activity in southern provinces and the emergence of the H3N2 strain, which has led to increased investor interest in pharmaceutical companies [1][2] Company Performance - **Jinshi Yiyao**: Increased by 13.44%, with a total market value of 4.644 billion [2] - **Guangji Pharmaceutical**: Rose by 9.97%, total market value of 2.448 billion [2] - **Te Yi Pharmaceutical**: Gained 8.78%, market value of 5.209 billion [2] - **Hualan Biological Engineering**: Up by 8.59%, with a market value of 12.9 billion [2] - **Lingkang Pharmaceutical**: Increased by 7.01%, market value of 4.291 billion [2] - **Hengdi Pharmaceutical**: Rose by 6.60%, market value of 5.466 billion [2] - **Innotec**: Increased by 5.37%, market value of 4.459 billion [2] - **Weikang Pharmaceutical**: Up by 4.76%, market value of 3.471 billion [2] - **Yirui Biological**: Increased by 4.67%, market value of 4.359 billion [2] Market Trends - The China CDC reported a slow increase in respiratory disease cases nationwide, with flu activity rising in southern provinces and remaining low in northern regions [1] - Experts suggest that the flu season may arrive earlier this year, with a potential increase in infection rates due to lower immunity against the H3N2 strain [1]

Core Viewpoint - Lingkang Pharmaceutical Group Co., Ltd. held its second extraordinary general meeting of shareholders on October 10, 2025, where the fifth board of directors was elected, and key management personnel were appointed [1][5]. Group 1: Board Composition - The fifth board of directors consists of 7 members: 3 non-independent directors, 3 independent directors, and 1 employee representative director [2][3]. - The board is chaired by Ms. Tao Lingping, with Mr. Tao Xiaogang, Mr. Zhang Hui as non-independent directors, and Mr. Wang Hongxin, Ms. Zhu Ming, and Ms. Du Juling as independent directors [2][3]. Group 2: Management Appointments - The company appointed Mr. Tao Xiaogang as the general manager, with Mr. Lü Jun, Mr. Liu Liming, and Mr. Sui Guoping as vice general managers [3][4]. - Mr. Zhang Junke was appointed as the financial director, Mr. Sui Guoping as the board secretary, and Mr. Liao Baoyu as the securities affairs representative [3][4]. Group 3: Committee Structure - The board has established four specialized committees: the Audit Committee, Nomination Committee, Compensation and Assessment Committee, and Strategic Committee, with independent directors holding a majority in the first three committees [3][4]. Group 4: Cancellation of Supervisory Board - The company decided to cancel the supervisory board, transferring its responsibilities to the Audit Committee of the board, in compliance with new regulations effective from July 1, 2024 [5][6]. Group 5: Shareholder Meeting Details - The extraordinary general meeting was legally convened, with all resolutions passed unanimously, including the election of the board and the cancellation of the supervisory board [11][17].

Core Viewpoint - Lingkang Pharmaceutical announced the election of Mr. Liu Liming as the employee representative director of the company's fifth board of directors [2] Company Summary - The announcement was made on the evening of October 10 [2] - The election reflects the company's governance structure and employee representation [2]

Group 1 - The core point of the article is that Lingkang Pharmaceutical announced the election of Ms. Tao Lingping as the new chairperson of the board [2][3]

关于选举第五届董事会职工代表董事的公告 证券代码：603669 证券简称：灵康药业 公告编号：2025-068 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 灵康药业集团股份有限公司 2025 年 10 月 11 日 1 刘力明简历： 刘力明，男，1975 年生，中国国籍，无境外永久居留权，大专学历，执业 药师、工程师。2007 年 6 月至 2017 年 5 月历任海南双成药业股份有限公司质量 管理部经理、QA 经理、设备管理部经理、生产技术部经理；2017 年 5 月至 2020 年 3 月任海南合瑞制药股份有限公司副总经理；2020 年 3 月至今历任海南灵康 制药有限公司生产副总经理，2024 年 4 月至今任公司董事兼副总经理；现任海 南灵康制药有限公司常务副总经理，公司职工代表董事兼副总经理。 2 根据《中华人民共和国公司法》等相关法律法规、规范性文件及《公司章程》 的有关规定，灵康药业集团股份有限公司（以下简称"公司"）于 2025 年 10 月 10 日召开 2025 年第一次职工代表大会，选举第五届董 ...

证券代码：603669 证券简称：灵康药业 公告编号：2025-067 灵康药业集团股份有限公司 关于董事会完成换届选举及聘任高级管理人员、证券 事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 灵康药业集团股份有限公司（以下简称"公司"）于 2025 年 10 月 10 日召开 2025 年第二次临时股东大会，会议选举产生了公司 3 名非独立董事及 3 名独立 董事，与公司职工代表大会选举产生的 1 名职工代表董事共同组成第五届董事会。 在完成董事会换届选举后，公司于同日召开第五届董事会第一次会议，选举产生 第五届董事会董事长、各专门委员会委员，并聘任了总经理、副总经理、财务总 监、董事会秘书和证券事务代表。现将公司董事会换届选举及聘任高级管理人员、 证券事务代表的具体情况公告如下： 一、公司第五届董事会组成情况 根据公司职工代表大会、2025 年第二次临时股东大会及第五届董事会第一 次会议选举结果，公司第五届董事会由 7 名董事组成，其中：非独立董事 3 名， 独立董事 3 名，职工代表董事 1 名。公 ...

证券代码：603669 证券简称：灵康药业 公告编号：2025-065 灵康药业集团股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 10 月 10 日 (二)股东大会召开的地点：浙江省杭州市上城区民心路 100 号万银国际大厦 27 层，浙江灵康药业有限公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 132 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 309,480,375 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 43.9888% | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，由公司董事长陶灵萍女士主持。本次会议的召 集、召开、表决方式符合 ...

上海东方华银律师事务所 法律意见书 上海东方华银律师事务所 关于灵康药业集团股份有限公司 上海东方华银律师事务所 法律意见书 上海东方华银律师事务所 关于灵康药业集团股份有限公司 2025 年第二次临时股东大会之法律意见书 致：灵康药业集团股份有限公司 2025 年第二次临时股东大会 之 法律意见书 上海东方华银律师事务所 上海市虹桥路 1591 号虹桥迎宾馆 34 号楼 电话：(8621) 68769686 上海东方华银律师事务所（以下简称"本所"）接受灵康药业集团股份有限 公司（以下简称"贵司"或"公司"）委托，就贵司召开 2025 年第二次临时股 东大会的有关事宜，根据《中华人民共和国公司法》（以下简称《公司法》）、 《上市公司股东会规则》（以下简称《股东会规则》）等法律、法规和其他规范 性文件以及《灵康药业集团股份有限公司章程》（以下简称《公司章程》）的有 关规定，出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的本次股东大会的相关资 料，包括但不限于公司召开 2025 年第二次临时股东大会的通知、公司 2025 年第 二次临时股东大会的议程、议案及决议等文件资料，同时听取了公司董事会秘 ...

会议选举陶灵萍女士为公司第五届董事会董事长，任期与第五届董事会任期 一致。 表决结果：同意票 7 票，反对票 0 票，弃权 0 票。 第五届董事会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 灵康药业集团股份有限公司（以下简称"公司"）第五届董事会第一次会议 通知于 2025 年 9 月 26 日以电话、电子邮件等形式发出，会议于 2025 年 10 月 10 日在浙江灵康药业有限公司会议室以现场方式召开。会议由董事长陶灵萍召 集并主持，应出席本次会议的董事 7 人，实际出席本次会议的董事 7 人。公司高 级管理人员列席了会议。本次会议的召集、召开和表决程序符合有关法律、法规 和《公司章程》的规定，会议形成的决议合法有效。 二、董事会会议审议情况 1、审议通过了《关于选举第五届董事会董事长的议案》 证券代码：603669 证券简称：灵康药业 公告编号：2025-066 灵康药业集团股份有限公司 1 3、审议通过了《关于聘任总经理的议案》 经董事长陶灵萍女士提名，董事会提名委员 ...